<DOC>
	<DOCNO>NCT01098721</DOCNO>
	<brief_summary>Psoriasis chronic inflammatory skin disorder characterize hyperproliferation keratinocytes inflammation epidermal dermal layer skin . This study , patient mild moderate plaque psoriasis , design determine efficacy , safety tolerability novel , topically apply , non-steroid , anti-inflammatory WBI-1001 cream period 12 week .</brief_summary>
	<brief_title>A Safety/Efficacy Study Non-steroid , Topical Cream Treatment Psoriasis Over 12-weeks</brief_title>
	<detailed_description>A double-blinded , placebo-controlled study . Following screening , eligible patient randomize Day 0 one two treatment group 1:2 ratio : Group 1 : placebo ( vehicle ) cream , twice daily ( BID ) . Group 2 : 1.0 % WBI-1001 cream , BID . Patients randomize treat treatable lesion area except face , scalp , groin genital area , instruct apply cream twice daily 84 day , time day , morning evening . During study patient visit study centre assessment efficacy , safety tolerability 0 , 14 , 28 , 56 84 day initiation , patient phone Day 112 follow-up safety assessment . Patients withdraw study Day 56 due reason adverse event replace necessary ensure least 16 patient placebo 32 active cream treat group remain study Day 56 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>A clinical diagnosis stable plaque psoriasis least 6 month represent maximum 10 % BSA minimum 1 % BSA exclude face , groin , scalp genital region minimum one target plaque least 2 x 2 cm size Day 0 . PGA 2 4 Day 0 . In good general health free disease state physical condition might impair evaluation plaque psoriasis . Women child bear potential ( WOCBP ) must negative serum betahuman chorionic gonadotrophin ( bhCG ) pregnancy test randomization . WOBCP abstinent sex male partner may enter study willing continue use adequate contraceptive precaution duration study . Male patient female sexual partner able become pregnant must ensure acceptable method birth control use study . Women lactate eligible study . Willing able comply protocol likely attend study visit . Provide write , informed consent prior initiation studyrelated procedure . Spontaneously improve rapidly deteriorate plaque psoriasis . Any skin disease might interfere clinical assessment plaque psoriasis and/or put patient risk . Pustular , erythrodermic nonplaque form pf psoriasis . Guttate psoriasis dominant form psoriasis . Other concomitant , serious illness medical condition ( eg. , human immunodeficiency virus , renal insufficiency , clinically significant abnormal laboratory value ) could put patient risk study . History neurological/psychiatric disorder , include psychotic disorder dementia , reason would interfere patient 's participation trial . Systemic immunomodulatory therapy know affect psoriasis decrease immune cell population ( eg. , alefacept ) within 24 week baseline visit . Systemic immunomodulatory therapy know affect psoriasis typically decrease immune cell population ( eg. , etanercept ) within 12 week prior baseline visit . Any phototherapy ( include laser treatment psoriasis ) , photochemotherapy , systemic psoriasis therapy ( systemic corticosteroid , methotrexate , retinoids cyclosporine ) within 4 week prior baseline visit . Prolonged exposure artificial natural source ultraviolet radiation within 4 week prior baseline visit intention exposure study , think investigator likely modify patient 's psoriasis . Topical antipsoriatic therapy ( include topical retinoids vitamin D analog ) area treat within 2 week prior baseline visit . Alcohol abuse last 2 year define consumption &gt; 14 standard drink alcohol per week . Use lithium within 2 week prior screen visit . Use beta blocker ( eg. , propranolol ) within 2 week prior screen visit unless stable dose &gt; 3 month . Known suspect hypersensitivity constituent investigational product . Treatment investigational drug within 1 month Day 0 current participation another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>skin disease</keyword>
	<keyword>anti-inflammatory</keyword>
	<keyword>non-steroid</keyword>
	<keyword>topical cream</keyword>
</DOC>